The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).
Edward B. Garon
Consultant or Advisory Role - Merck (U)
Research Funding - Merck
Natasha B. Leighl
No relevant relationships to disclose
Naiyer A. Rizvi
No relevant relationships to disclose
George R. Blumenschein
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Immunogen
Research Funding - Bayer; Genentech; GlaxoSmithKline; MedImmune; Merck; Novartis; Xcovery
Ani Sarkis Balmanoukian
No relevant relationships to disclose
Joseph Paul Eder
No relevant relationships to disclose
Jonathan Wade Goldman
No relevant relationships to disclose
Rina Hui
No relevant relationships to disclose
Jean-Charles Soria
No relevant relationships to disclose
Tara C. Gangadhar
No relevant relationships to disclose
Jong-Mu Sun
No relevant relationships to disclose
Amita Patnaik
Research Funding - Merck
Matthew A. Gubens
Research Funding - Merck
Gregory M. Lubiniecki
Employment or Leadership Position - Merck
Jin Zhang
Employment or Leadership Position - Merck
Michelle Niewood
Employment or Leadership Position - Merck
Kenneth Emancipator
Employment or Leadership Position - Merck
Marisa Dolled-Filhart
Employment or Leadership Position - Merck
Mary Elizabeth Hanson
Employment or Leadership Position - Merck
Stock Ownership - Merck
Leena Gandhi
No relevant relationships to disclose